4.82 0.22 (4.78%)

48.34% Fall from 52W High

5.1M XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Low Financial Strength
27.8 / 100
Expensive Valuation
12.7 / 100
Technically Neutral
38.7 / 100
Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

Ardelyx Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Chart titleHighcharts.com

Consensus Recommendation

Created with Highcharts 7.2.22Hold9Strong Buy
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Ardelyx Inc Stock Analysis

Ardelyx Inc stock analysis with key metrics, changes, and trends.

Ardelyx Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$333.62 M168.06%positive

Annual Revenue rose 168.06%, in the last year to $333.62 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit$39.14 M40.76%positive

Annual Net Profit rose 40.76% in the last year to $39.14 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio-29.36-negative

Price to Earning Ratio is -29.36, which is negative.

Stock Price$4.82-25.62%negative

Stock Price fell 25.62% and underperformed its sector by 32.95% in the past year.

Quarterly Revenue$116.13 M237.95%positive

Quarterly Revenue rose 237.95% YoY to $116.13 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit$4.64 M116.13%positive

Quarterly Net profit rose 116.13% YoY to $4.64 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio0.89-positive

Debt to Equity Ratio of 0.89 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-23.01 %-23.01%negative

Return on Equity(ROE) for the last financial year was -23.01%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding47.28 %-0.36%negative

Mutual Fund Holding decreased by 0.36% in the last quarter to 47.28.

Promoter Share Holding10.96 %1.65%positive

Promoter Share Holding increased by 1.65% in the most recent quarter to 10.96%.

Interest Coverage Ratio-0.93-negative

Interest Coverage Ratio is -0.93, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding63.37 %0.02%positive

Institutional Holding increased by 0.02% in the last quarter to 63.37.

VIEW LESS


Loading data..

Ardelyx Inc - Company Profile

What does Ardelyx Inc do?

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ardelyx Inc Management structure

All Gross Remunerations are in USD
Mr. Robert Felsch
Chief Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Joseph Reilly
Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Justin A. Renz
Chief Financial and Operations Officer
-
2024
Gross Remuneration
Year
Mr. Michael G. Raab
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

Ardelyx Inc Board of directors

All Gross Remunerations are in USD
Mr. Richard J. Rodgers
Independent Director
-
2024
Gross Remuneration
Year
Mr. William C. Bertrand, Esq.,Jr
Independent Director
-
2024
Gross Remuneration
Year
Mr. David M. Mott
Chairman of the Board
-
2024
Gross Remuneration
Year
Mr. Michael G. Raab
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. Robert B. Bazemore, Jr
Independent Director
-
2024
Gross Remuneration
Year
Ms. Onaiza Cadoret-Manier
Independent Director
-
2024
Gross Remuneration
Year

Ardelyx Inc FAQ

How is Ardelyx Inc today?
Ardelyx Inc today is trading in the green, and is up by 4.78% at 4.82.
Ardelyx Inc is currently trading up 4.78% on an intraday basis. In the past week the stock rose 8.07%. stock has been down -3.79% in the past quarter and fell -25.62% in the past year. You can view this in the overview section.